Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Melphalan versus cyclophosphamide combined with fludarabine and low dose total body irradiation (TBI) prior to ptcy-based allogeneic transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAsad Bashey

Discussion

Loading...

Member takes

Overview

Observations highlight that melphalan led to lower relapse incidence but higher non-relapse mortality in transplant patients.

Key Points

  • This research aims to compare the efficacy of melphalan versus cyclophosphamide in nonmyeloablative allogeneic transplantation.
  • Compared FM-TBI and FC-TBI regimens in consecutive patients with hematologic malignancy.
  • Evaluated engraftment times, incidence of GVHD, NRM, and overall survival rates.
  • Conducted multivariable analysis controlled for diagnosis and DRI.
  • FM-TBI led to lower 1-year relapse incidence of 7% compared to 23% for FC-TBI.
  • FM-TBI resulted in higher 1-year non-relapse mortality at 36% versus 7% for FC-TBI.
  • Engraftment was slower in FM-TBI patients with longer hospital stays.

Cite This Study

Asad Bashey (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d887https://doi.org/10.1182/blood-2025-4194
View Full Paper
Ask AI
Bookmark
Share